Adria Hasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Adria Hasan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Snober Shabnam Mir
Molecular Cell Biology Laboratory, Integral Centre of Excellence for Interdisciplinary Research (ICEIR-4), Integral University, Kursi Road, Lucknow, 226026, India; Department of Biosciences, Faculty of Science, Integral University, Kursi Road, Lucknow, 226026, India
2 shared publications - Abdul Malik
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
1 shared publication - Ahamad Faiz Khan
Department of Bioengineering, Faculty of Engineering, Integral University, Lucknow, India
1 shared publication - Jamal- E- Fatima
School of Electronic Science and Engineering, Biomedical Imaging and Electrophysiology Lab, University of Electronic Science and Technology of China, Chengdu, China
1 shared publication - Sana Parveen1 shared publication
- Shoeb Ikhlas
King Abdullah International Medical Research Center (KAIMRC), Riyadh 11481, Saudi Arabia
1 shared publication
Latest Publications
- 4 June 2025
- Published by Elsevier in Food Bioscience
- Vol. 71
Identification of DNMT modulators as potential anti-cancer agents using pharmacoinformatics approach
- 4 June 2025
- Published by Elsevier in Food Bioscience
- Vol. 71
Identification of DNMT modulators as potential anti-cancer agents using pharmacoinformatics approach
- Open Access
- 20 December 2022
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (3) , 2701-2711
Therapeutic role of mTOR inhibitors in control of SARS-CoV-2 viral replication
By the end of 2019, COVID-19 was reported in Wuhan city of China, and through human-human transmission, this virus spread worldwide and became a pandemic. Initial symptoms of the disease include fever, cough, loss of smell, taste, and shortness of breath, but a decrease in the oxygen levels in the body leads, and pneumonia may ultimately lead to the patient’s death. However, the symptoms vary from patient to patient. To understand COVID-19 disease pathogenesis, researchers have tried to understand the cellular pathways that could be targeted to suppress viral replication. Thus, this article reviews the markers that could be targeted to inhibit viral replication by inhibiting the translational initiation complex/regulatory kinases and upregulating host autophagic flux that may lead to a reduction in the viral load. The article also highlights that mTOR inhibitors may act as potential inhibitors of viral replication. mTOR inhibitors such as metformin may inhibit the interaction of SARS-CoV-2 Nsp’s and ORFs with mTORC1, LARP1, and 4E-BP. They may also increase autophagic flux by decreasing protein degradation via inhibition of Skp2, further promoting viral cell death. These events result in cell cycle arrest at G1 by p27, ultimately causing cell death. Graphical Abstract
- 20 December 2022
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (3) , 2701-2711
Open AccessTherapeutic role of mTOR inhibitors in control of SARS-CoV-2 viral replication
By the end of 2019, COVID-19 was reported in Wuhan city of China, and through human-human transmission, this virus spread worldwide and became a pandemic. Initial symptoms of the disease include fever, cough, loss of smell, taste, and shortness of breath, but a decrease in the oxygen levels in the body leads, and pneumonia may ultimately lead to the patient’s death. However, the symptoms vary from patient to patient. To understand COVID-19 disease pathogenesis, researchers have tried to understand the cellular pathways that could be targeted to suppress viral replication. Thus, this article reviews the markers that could be targeted to inhibit viral replication by inhibiting the translational initiation complex/regulatory kinases and upregulating host autophagic flux that may lead to a reduction in the viral load. The article also highlights that mTOR inhibitors may act as potential inhibitors of viral replication. mTOR inhibitors such as metformin may inhibit the interaction of SARS-CoV-2 Nsp’s and ORFs with mTORC1, LARP1, and 4E-BP. They may also increase autophagic flux by decreasing protein degradation via inhibition of Skp2, further promoting viral cell death. These events result in cell cycle arrest at G1 by p27, ultimately causing cell death. Graphical Abstract